Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Hepcidin-guided screen-and-treat interventions against iron-deficiency anaemia in pregnancy: a randomised controlled trial in The Gambia.

Bah A, Muhammad AK, Wegmuller R, Verhoef H, Goheen MM, Sanyang S, Danso E, Sise EA, Pasricha SR, Armitage AE, Drakesmith H, Cross JH, Moore SE, Cerami C, Prentice AM.

Lancet Glob Health. 2019 Nov;7(11):e1564-e1574. doi: 10.1016/S2214-109X(19)30393-6.

2.

Community-acquired Invasive Bacterial Disease in Urban Gambia, 2005-2015: A Hospital-based Surveillance.

Darboe S, Okomo U, Muhammad AK, Ceesay B, Jallow M, Usuf E, Tweed S, Akpalu E, Kwambana-Adams B, Kariuki S, Antonio M, Bradbury RS, Forrest K, de Silva TI, Lawal BJ, Nwakanma D, Secka O, Roca A.

Clin Infect Dis. 2019 Sep 5;69(Supplement_2):S105-S113. doi: 10.1093/cid/ciz463.

3.

Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model.

Zhou Y, Carmona S, Muhammad AKMG, Bell S, Landeros J, Vazquez M, Ho R, Franco A, Lu B, Dorn GW 2nd, Wang S, Lutz CM, Baloh RH.

J Clin Invest. 2019 Mar 18;130:1756-1771. doi: 10.1172/JCI124194. eCollection 2019 Mar 18.

4.

Cell transplantation strategies for acquired and inherited disorders of peripheral myelin.

Muhammad AKMG, Kim K, Epifantseva I, Aghamaleky-Sarvestany A, Simpkinson ME, Carmona S, Landeros J, Bell S, Svaren J, Baloh RH.

Ann Clin Transl Neurol. 2018 Jan 22;5(2):186-200. doi: 10.1002/acn3.517. eCollection 2018 Feb.

5.

The Immunogenicity of Fractional Intradermal Doses of the Inactivated Poliovirus Vaccine Is Associated With the Size of the Intradermal Fluid Bleb.

Bibby J, Saidu Y, Umesi A, Moneke-Anyanwoke N, Bashorun AO, Hydara MB, Adigweme I, Adetifa JU, Okoye M, Roberts E, Clemens R, Bandyopadhyay AS, Muhammad AK, Mulwa S, Royals M, Jarrahian C, Jeffries D, Kampmann B, Clarke E.

Clin Infect Dis. 2017 Sep 1;65(5):851-854. doi: 10.1093/cid/cix381.

6.

Prevalence of intimate partner violence and abuse and associated factors among women enrolled into a cluster randomised trial in northwestern Tanzania.

Kapiga S, Harvey S, Muhammad AK, Stöckl H, Mshana G, Hashim R, Hansen C, Lees S, Watts C.

BMC Public Health. 2017 Feb 14;17(1):190. doi: 10.1186/s12889-017-4119-9.

7.

C9orf72 is required for proper macrophage and microglial function in mice.

O'Rourke JG, Bogdanik L, Yáñez A, Lall D, Wolf AJ, Muhammad AK, Ho R, Carmona S, Vit JP, Zarrow J, Kim KJ, Bell S, Harms MB, Miller TM, Dangler CA, Underhill DM, Goodridge HS, Lutz CM, Baloh RH.

Science. 2016 Mar 18;351(6279):1324-9. doi: 10.1126/science.aaf1064.

8.

C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD.

O'Rourke JG, Bogdanik L, Muhammad AKMG, Gendron TF, Kim KJ, Austin A, Cady J, Liu EY, Zarrow J, Grant S, Ho R, Bell S, Carmona S, Simpkinson M, Lall D, Wu K, Daughrity L, Dickson DW, Harms MB, Petrucelli L, Lee EB, Lutz CM, Baloh RH.

Neuron. 2015 Dec 2;88(5):892-901. doi: 10.1016/j.neuron.2015.10.027.

9.

A Tuberculin Skin Test Survey and the Annual Risk of Mycobacterium tuberculosis Infection in Gambian School Children.

Adetifa IM, Muhammad AK, Jeffries D, Donkor S, Borgdorff MW, Corrah T, D'Alessandro U.

PLoS One. 2015 Oct 14;10(10):e0139354. doi: 10.1371/journal.pone.0139354. eCollection 2015.

10.

Malaria Prevalence among Young Infants in Different Transmission Settings, Africa.

Ceesay SJ, Koivogui L, Nahum A, Taal MA, Okebe J, Affara M, Kaman LE, Bohissou F, Agbowai C, Tolno BG, Amambua-Ngwa A, Bangoura NF, Ahounou D, Muhammad AK, Duparc S, Hamed K, Ubben D, Bojang K, Achan J, D'Alessandro U.

Emerg Infect Dis. 2015 Jul;21(7):1114-21. doi: 10.3201/eid2107.142036.

11.

School-based countrywide seroprevalence survey reveals spatial heterogeneity in malaria transmission in the Gambia.

Okebe J, Affara M, Correa S, Muhammad AK, Nwakanma D, Drakeley C, D'Alessandro U.

PLoS One. 2014 Oct 22;9(10):e110926. doi: 10.1371/journal.pone.0110926. eCollection 2014.

12.

Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H.

Lynes J, Wibowo M, Koschmann C, Baker GJ, Saxena V, Muhammad AK, Bondale N, Klein J, Assi H, Lieberman AP, Castro MG, Lowenstein PR.

Neurotherapeutics. 2014 Jul;11(3):623-35. doi: 10.1007/s13311-014-0269-y.

13.

Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion.

Sareen D, O'Rourke JG, Meera P, Muhammad AK, Grant S, Simpkinson M, Bell S, Carmona S, Ornelas L, Sahabian A, Gendron T, Petrucelli L, Baughn M, Ravits J, Harms MB, Rigo F, Bennett CF, Otis TS, Svendsen CN, Baloh RH.

Sci Transl Med. 2013 Oct 23;5(208):208ra149. doi: 10.1126/scitranslmed.3007529.

14.

Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.

Mineharu Y, Muhammad AK, Yagiz K, Candolfi M, Kroeger KM, Xiong W, Puntel M, Liu C, Levy E, Lugo C, Kocharian A, Allison JP, Curran MA, Lowenstein PR, Castro MG.

Neurotherapeutics. 2012 Oct;9(4):827-43. doi: 10.1007/s13311-012-0144-7.

15.

Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.

Candolfi M, King GD, Yagiz K, Curtin JF, Mineharu Y, Muhammad AK, Foulad D, Kroeger KM, Barnett N, Josien R, Lowenstein PR, Castro MG.

Neoplasia. 2012 Aug;14(8):757-70.

16.

Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial.

Muhammad AK, Xiong W, Puntel M, Farrokhi C, Kroeger KM, Salem A, Lacayo L, Pechnick RN, Kelson KR, Palmer D, Ng P, Liu C, Lowenstein PR, Castro MG.

Hum Gene Ther Methods. 2012 Aug;23(4):271-84. doi: 10.1089/hgtb.2012.060. Epub 2012 Sep 5.

17.

B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.

Candolfi M, Curtin JF, Yagiz K, Assi H, Wibowo MK, Alzadeh GE, Foulad D, Muhammad AK, Salehi S, Keech N, Puntel M, Liu C, Sanderson NR, Kroeger KM, Dunn R, Martins G, Lowenstein PR, Castro MG.

Neoplasia. 2011 Oct;13(10):947-60.

18.

Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.

Mineharu Y, King GD, Muhammad AK, Bannykh S, Kroeger KM, Liu C, Lowenstein PR, Castro MG.

Clin Cancer Res. 2011 Jul 15;17(14):4705-18. doi: 10.1158/1078-0432.CCR-11-0915. Epub 2011 Jun 1.

19.

Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.

King GD, Muhammad AK, Larocque D, Kelson KR, Xiong W, Liu C, Sanderson NS, Kroeger KM, Castro MG, Lowenstein PR.

Mol Ther. 2011 Oct;19(10):1793-801. doi: 10.1038/mt.2011.77. Epub 2011 Apr 19.

20.

Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.

Kroeger KM, Muhammad AK, Baker GJ, Assi H, Wibowo MK, Xiong W, Yagiz K, Candolfi M, Lowenstein PR, Castro MG.

Discov Med. 2010 Oct;10(53):293-304. Review.

21.

Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.

Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Kroeger KM, Tesarfreund M, Lee S, Debinski W, Sareen D, Svendsen CN, Rodriguez R, Lowenstein PR, Castro MG.

Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20021-6. doi: 10.1073/pnas.1008261107. Epub 2010 Oct 28.

22.

Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.

Xiong W, Candolfi M, Liu C, Muhammad AK, Yagiz K, Puntel M, Moore PF, Avalos J, Young JD, Khan D, Donelson R, Pluhar GE, Ohlfest JR, Wawrowsky K, Lowenstein PR, Castro MG.

PLoS One. 2010 Jun 11;5(6):e11074. doi: 10.1371/journal.pone.0011074.

23.

A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics.

Puntel M, Muhammad AK, Candolfi M, Salem A, Yagiz K, Farrokhi C, Kroeger KM, Xiong W, Curtin JF, Liu C, Bondale NS, Lerner J, Pechnick RN, Palmer D, Ng P, Lowenstein PR, Castro MG.

J Virol. 2010 Jun;84(12):6007-17. doi: 10.1128/JVI.00398-10. Epub 2010 Apr 7.

24.

Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.

Muhammad AK, Puntel M, Candolfi M, Salem A, Yagiz K, Farrokhi C, Kroeger KM, Xiong W, Curtin JF, Liu C, Lawrence K, Bondale NS, Lerner J, Baker GJ, Foulad D, Pechnick RN, Palmer D, Ng P, Lowenstein PR, Castro MG.

Clin Pharmacol Ther. 2010 Aug;88(2):204-13. doi: 10.1038/clpt.2009.260. Epub 2010 Feb 17.

25.

Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.

Candolfi M, Kroeger KM, Muhammad AK, Yagiz K, Farrokhi C, Pechnick RN, Lowenstein PR, Castro MG.

Curr Gene Ther. 2009 Oct;9(5):409-21. Review.

26.

Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.

Candolfi M, Yagiz K, Foulad D, Alzadeh GE, Tesarfreund M, Muhammad AK, Puntel M, Kroeger KM, Liu C, Lee S, Curtin JF, King GD, Lerner J, Sato K, Mineharu Y, Xiong W, Lowenstein PR, Castro MG.

Clin Cancer Res. 2009 Jul 1;15(13):4401-14. doi: 10.1158/1078-0432.CCR-09-0155.

27.

HMGB1 mediates endogenous TLR2 activation and brain tumor regression.

Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, Liu C, Muhammad AK, Clark MC, Arditi M, Comin-Anduix B, Ribas A, Lowenstein PR, Castro MG.

PLoS Med. 2009 Jan 13;6(1):e10. doi: 10.1371/journal.pmed.1000010.

28.

Herpes simplex virus type 1 thymidine kinase sequence fused to the lacz gene increases levels of {beta}-galactosidase activity per genome of high-capacity but not first-generation adenoviral vectors in vitro and in vivo.

Puntel M, Barrett RJ, Mondkar S, Saxena V, Kroeger KM, Muhammad AK, Liu C, Bondale N, Sciascia S, Xiong W, Shi Y, Salem A, Zadmehr A, Huynh P, Palmer D, Ng P, Castro MG, Lowenstein PR.

J Virol. 2009 Feb;83(4):2004-10. doi: 10.1128/JVI.01298-08. Epub 2008 Dec 10.

29.

Regulated expression of adenoviral vectors-based gene therapies: therapeutic expression of toxins and immune-modulators.

Curtin JF, Candolfi M, Puntel M, Xiong W, Muhammad AK, Kroeger K, Mondkar S, Liu C, Bondale N, Lowenstein PR, Castro MG.

Methods Mol Biol. 2008;434:239-66. doi: 10.1007/978-1-60327-248-3_15.

30.

High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity.

King GD, Muhammad AK, Xiong W, Kroeger KM, Puntel M, Larocque D, Palmer D, Ng P, Lowenstein PR, Castro MG.

J Virol. 2008 May;82(9):4680-4. doi: 10.1128/JVI.00232-08. Epub 2008 Feb 20. Erratum in: J Virol. 2008 Jun;82(12):6087.

31.

Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.

King GD, Kroeger KM, Bresee CJ, Candolfi M, Liu C, Manalo CM, Muhammad AK, Pechnick RN, Lowenstein PR, Castro MG.

Mol Ther. 2008 Apr;16(4):682-90. doi: 10.1038/mt.2008.18. Epub 2008 Feb 19.

32.

Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.

King GD, Muhammad AK, Curtin JF, Barcia C, Puntel M, Liu C, Honig SB, Candolfi M, Mondkar S, Lowenstein PR, Castro MG.

Neuro Oncol. 2008 Feb;10(1):19-31. Epub 2007 Dec 13.

33.

Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.

Candolfi M, Pluhar GE, Kroeger K, Puntel M, Curtin J, Barcia C, Muhammad AK, Xiong W, Liu C, Mondkar S, Kuoy W, Kang T, McNeil EA, Freese AB, Ohlfest JR, Moore P, Palmer D, Ng P, Young JD, Lowenstein PR, Castro MG.

Neuro Oncol. 2007 Jul;9(3):245-58. Epub 2007 May 23.

34.

Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction.

Puntel M, Curtin JF, Zirger JM, Muhammad AK, Xiong W, Liu C, Hu J, Kroeger KM, Czer P, Sciascia S, Mondkar S, Lowenstein PR, Castro MG.

Hum Gene Ther. 2006 May;17(5):531-44.

35.

Syringe needle located deep in the brain: image-guided removal.

Muhammad AK, Maruno M, Maeda N, Kato A, Yoshimine T.

Surg Neurol. 2000 Dec;54(6):458-63; discussion 463-4.

PMID:
11240179
36.

Ultrastructural changes of the vascular endothelium after intra-arterial administration of tumor necrosis factor-alpha (TNFalpha) in rat gliomas.

Isaka T, Maruno M, Muhammad AK, Kato A, Nakagawa H, Yoshimine T.

J Neurooncol. 2000;46(2):145-50.

PMID:
10894367
37.

Chromosomal aberrations detected by comparative genomic hybridization (CGH) in human astrocytic tumors.

Maruno M, Yoshimine T, Muhammad AK, Ninomiya H, Kato A, Hayakawa T.

Cancer Lett. 1999 Jan 8;135(1):61-6.

PMID:
10077222
38.

Chromosomal losses and gains in meningiomas: comparative genomic hybridization (CGH) study of the whole genome.

Maruno M, Yoshimine T, Muhammad AK, Ninomiya H, Hayakawa T.

Neurol Res. 1998 Oct;20(7):612-6.

PMID:
9785589
39.

Distribution of nerve growth factor in cat brains following topical application of solution or Minipellet.

Takemoto O, Yoshimine T, Muhammad AK, Maruno M, Yamamoto S, Fujioka K, Koseki N, Takada Y, Sano A, Maeda H, Hayakawa T.

Neurol Res. 1998 Mar;20(2):116-20.

PMID:
9522345
40.

Chromosome 22q allelic losses at microsatellite loci in human astrocytic tumors.

Muhammad AK, Yoshimine T, Maruno M, Tokiyoshi K, Takemoto O, Hayakawa T.

Neurol Med Chir (Tokyo). 1997 Aug;37(8):606-10; discussion 611.

41.

Chromosome 17 allelic loss in astrocytic tumors and its clinico-pathologic implications.

Muhammad AK, Yoshimine T, Maruno M, Tokiyoshi K, Takemoto O, Ninomiya H, Hayakawa T.

Clin Neuropathol. 1997 Jul-Aug;16(4):220-6.

PMID:
9266149
42.

Loss of heterozygosity of microsatellite loci on chromosome 9p in astrocytic tumors and its prognostic implications.

Maruno M, Yoshimine T, Muhammad AK, Tokiyoshi K, Hayakawa T.

J Neurooncol. 1996 Oct;30(1):19-24.

PMID:
8864999
43.

Accumulation of allelic losses on chromosome 10 in human gliomas at recurrence.

Tokiyoshi K, Yoshimine T, Maruno M, Muhammad AK, Hayakawa T.

Clin Mol Pathol. 1996 Aug;49(4):M218-22.

Supplemental Content

Loading ...
Support Center